# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it w...
Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, presented a poster titled...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Biora Therapeutics (NASDAQ:BIOR) with a Buy and maintains $15 pr...
Biora Therapeutics (NASDAQ:BIOR) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(...
Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it w...